These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 27325652)

  • 41. PRL1 and PRL3 promote macropinocytosis via its lipid phosphatase activity.
    Ye Z; Ng CP; Liu H; Bao Q; Xu S; Zu D; He Y; Huang Y; Al-Aidaroos AQO; Guo K; Li J; Yaw LP; Xiong Q; Thura M; Zheng W; Guan F; Cheng X; Shi Y; Zeng Q
    Theranostics; 2024; 14(9):3423-3438. PubMed ID: 38948056
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Expression of phosphatase of regenerating liver-3 in gastric cancer, its relationship with prognosis, and its role in gastric cancer cell proliferation].
    Cai SR; Chen CQ; Wang Z; He YL; Cui J; Wu WH; Wu H; Zhan WH
    Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(33):2326-30. PubMed ID: 19087692
    [TBL] [Abstract][Full Text] [Related]  

  • 43. DUSP1 expression induced by HDAC1 inhibition mediates gefitinib sensitivity in non-small cell lung cancers.
    Lin YC; Lin YC; Shih JY; Huang WJ; Chao SW; Chang YL; Chen CC
    Clin Cancer Res; 2015 Jan; 21(2):428-38. PubMed ID: 25593344
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PRL-3 phosphatase is implicated in ovarian cancer growth.
    Polato F; Codegoni A; Fruscio R; Perego P; Mangioni C; Saha S; Bardelli A; Broggini M
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6835-9. PubMed ID: 16203771
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phosphatase, pseudo-phosphatase, or both? Understanding PRL oncogenicity.
    Gehring K; Miki H
    Br J Cancer; 2021 Mar; 124(6):1035-1036. PubMed ID: 33268817
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The essential role of FKBP38 in regulating phosphatase of regenerating liver 3 (PRL-3) protein stability.
    Choi MS; Min SH; Jung H; Lee JD; Lee TH; Lee HK; Yoo OJ
    Biochem Biophys Res Commun; 2011 Mar; 406(2):305-9. PubMed ID: 21320469
    [TBL] [Abstract][Full Text] [Related]  

  • 47. LEO1 is regulated by PRL-3 and mediates its oncogenic properties in acute myelogenous leukemia.
    Chong PS; Zhou J; Cheong LL; Liu SC; Qian J; Guo T; Sze SK; Zeng Q; Chng WJ
    Cancer Res; 2014 Jun; 74(11):3043-53. PubMed ID: 24686170
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Proteomic analysis identifies translationally controlled tumor protein as a mediator of phosphatase of regenerating liver-3-promoted proliferation, migration and invasion in human colon cancer cells.
    Chu ZH; Liu L; Zheng CX; Lai W; Li SF; Wu H; Zeng YJ; Zhao HY; Guan YF
    Chin Med J (Engl); 2011 Nov; 124(22):3778-85. PubMed ID: 22340241
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting ALDH1 to decrease tumorigenicity, growth and metastasis of human melanoma.
    Yue L; Huang ZM; Fong S; Leong S; Jakowatz JG; Charruyer-Reinwald A; Wei M; Ghadially R
    Melanoma Res; 2015 Apr; 25(2):138-48. PubMed ID: 25643237
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Therapeutic Targeting of Oncogenic Tyrosine Phosphatases.
    Frankson R; Yu ZH; Bai Y; Li Q; Zhang RY; Zhang ZY
    Cancer Res; 2017 Nov; 77(21):5701-5705. PubMed ID: 28855209
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phosphatase of regenerating liver-3 inhibits invasiveness and proliferation in non-small cell lung cancer by regulating the epithelial-mesenchymal transition.
    Lin SY; Lee YX; Yu SL; Chang GC; Chen JJ
    Oncotarget; 2016 Apr; 7(16):21799-811. PubMed ID: 26967563
    [TBL] [Abstract][Full Text] [Related]  

  • 52. mTORC1-Driven Tumor Cells Are Highly Sensitive to Therapeutic Targeting by Antagonists of Oxidative Stress.
    Li J; Shin S; Sun Y; Yoon SO; Li C; Zhang E; Yu J; Zhang J; Blenis J
    Cancer Res; 2016 Aug; 76(16):4816-27. PubMed ID: 27197195
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Elevated phosphatase of regenerating liver 3 (PRL-3) promotes cytoskeleton reorganization, cell migration and invasion in endometrial stromal cells from endometrioma.
    Zhan H; Ma J; Ruan F; Bedaiwy MA; Peng B; Wu R; Lin J
    Hum Reprod; 2016 Apr; 31(4):723-33. PubMed ID: 26874360
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance.
    Arnst KE; Wang Y; Hwang DJ; Xue Y; Costello T; Hamilton D; Chen Q; Yang J; Park F; Dalton JT; Miller DD; Li W
    Cancer Res; 2018 Jan; 78(1):265-277. PubMed ID: 29180476
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PRL-3 promotes the proliferation of LoVo cells via the upregulation of KCNN4 channels.
    Lai W; Chen S; Wu H; Guan Y; Liu L; Zeng Y; Zhao H; Jiang J; Chu Z
    Oncol Rep; 2011 Oct; 26(4):909-17. PubMed ID: 21725609
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The phosphatase of regenerating liver-3 (PRL-3) is important for IL-6-mediated survival of myeloma cells.
    Slørdahl TS; Abdollahi P; Vandsemb EN; Rampa C; Misund K; Baranowska KA; Westhrin M; Waage A; Rø TB; Børset M
    Oncotarget; 2016 May; 7(19):27295-306. PubMed ID: 27036022
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rebound Effects Caused by Withdrawal of MET Kinase Inhibitor Are Quenched by a MET Therapeutic Antibody.
    Pupo E; Ducano N; Lupo B; Vigna E; Avanzato D; Perera T; Trusolino L; Lanzetti L; Comoglio PM
    Cancer Res; 2016 Sep; 76(17):5019-29. PubMed ID: 27364553
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PRL-3 Promotes the Malignant Progression of Melanoma via Triggering Dephosphorylation and Cytoplasmic Localization of NHERF1.
    Fang XY; Song R; Chen W; Yang YY; Gu YH; Shu YQ; Wu XD; Wu XF; Sun Y; Shen Y; Xu Q
    J Invest Dermatol; 2015 Sep; 135(9):2273-2282. PubMed ID: 25897829
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Role of silencing PRL-3 expression by miRNA interference in the growth of gastric cancer].
    Cai SR; Wang Z; Chen CQ; Cui J; Zhang CH; He YL; Zhan WH
    Zhonghua Wai Ke Za Zhi; 2008 Apr; 46(8):618-21. PubMed ID: 18844061
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity.
    Komatsu Y; Tomizaki KY; Tsukamoto M; Kato T; Nishino N; Sato S; Yamori T; Tsuruo T; Furumai R; Yoshida M; Horinouchi S; Hayashi H
    Cancer Res; 2001 Jun; 61(11):4459-66. PubMed ID: 11389076
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.